Surprisingly, we observed low expression of the glycolytic enzyme PKM2 in PKM2-expressing cervical cancer patient tissues following chemotherapy, suggesting cervical cancer cells adapt to cisplatin’s toxicity by relying less on aerobic glycolysis pathways. Here, PKM is linked to cervical carcinoma.